Welcome to our dedicated page for CytomX Therapeutics SEC filings (Ticker: CTMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CytomX Therapeutics filings document a Delaware clinical-stage oncology biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under CTMX. Recent 8-K reports furnish quarterly and annual financial results, business updates, clinical-program disclosures for Varseta-M and other PROBODY programs, and clinical safety reporting tied to the company’s development studies.
Its formal records also cover capital structure and financing activity, including a completed public offering of common stock and pre-funded warrants made through a Form S-3 registration framework. Proxy materials describe board elections, auditor ratification, authorized-share amendments, equity incentive plan matters, executive compensation, and stockholder voting procedures.
Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report a shared beneficial ownership stake of 9,680,185 shares in CytomX Therapeutics, representing 5.9% of the outstanding common stock based on 164,912,906 shares outstanding. The Master Fund directly holds the shares, while Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, may be deemed to beneficially own those shares. All three reporting persons disclose no sole voting or dispositive power and shared voting and dispositive power over the reported shares.
OrbiMed Advisors LLC reported beneficial ownership of 8,461,500 shares of CytomX Therapeutics common stock, representing 5.4% of the class. The Schedule 13G filing states OrbiMed has shared voting and dispositive power over all reported shares and no sole voting or dispositive power. The filing identifies the reporting person as an investment adviser organized in Delaware and confirms these shares are held on behalf of other persons. The filing includes a certification that the position was not acquired to change or influence control of the issuer.
Point72 entities and Steven A. Cohen reported a 5.1% passive stake in CytomX Therapeutics (CTMX). The filing shows 8,084,623 shares are beneficially owned jointly by Point72 Asset Management, Point72 Capital Advisors and Mr. Cohen, with shared voting and dispositive power and no sole voting or dispositive power reported. The disclosure states these shares are held through Point72 Associates and that the positions were not acquired to influence control of the company. Ownership totals are reported as of the close of business on June 30, 2025.
Tang Capital Management and related entities report ownership of 11,065,662 shares of CytomX Therapeutics common stock, representing 7.0% of the outstanding class. The filing shows no sole voting or dispositive power; all reported shares are held with shared voting and dispositive power. The percentages are calculated using 157,544,369 shares outstanding per the issuer prospectus. The filers certify the stake is not held to influence control of the company.
On August 13, 2025, CytomX Therapeutics provided an update on its CX-2051 Phase 1 study. Dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg, given every three weeks, have each enrolled approximately 20 patients as planned. The company reported a single Grade 5 treatment-related acute kidney injury in a patient with a complex medical history, including a solitary kidney; the event was believed to be secondary to nausea, vomiting and diarrhea and was reported to the FDA on July 18, 2025. The study's Safety Review Committee convened on July 14, 2025 and supported continued study execution and enrollment.
The CTMX-2051-101 study remains ongoing and a Phase 1 data update is expected by Q1 2026. The filing discloses enrollment progress, the serious adverse event and regulatory reporting but does not provide additional efficacy or broader safety data.
CytomX Therapeutics (CTMX) filed a Form S-8 on 7 Aug 2025 to register 4,381,320 additional common shares for issuance under its Amended & Restated 2015 Equity Incentive Plan. The statement incorporates eleven prior S-8 filings and updates only the exhibit section (legal opinion, auditor consent, revised plan documents).
The company is classified as an accelerated filer and a smaller reporting company. Shares will be issued as option grants, RSUs or other awards vest and are exercised; no immediate cash proceeds are expected. Although the filing does not include financial results, the newly registered shares expand the equity pool, enabling continued employee compensation but creating potential dilution for existing shareholders. All required signatures, powers of attorney and fee calculations are provided.
CytomX Therapeutics (CTMX) Q2-25 10-Q snapshot
Six-month collaboration revenue inched up 4% YoY to $69.6 million, buoyed by Astellas milestones and BMS research fees. Tight cost control (R&D –32% to $32.2 million; G&A flat at $16.1 million) flipped YTD operating loss into a $23.4 million net profit (vs. $7.3 million profit LY), largely from $61.8 million of deferred-revenue recognition tied to Amgen and BMS program terminations. Q2 revenue fell 26% YoY to $18.7 million, producing a modest $0.2 million quarterly loss.
Liquidity strengthened: cash, equivalents and Treasuries rose to $159.5 million (Dec-24: $101.9 million) on a $93.4 million May follow-on offering. Share count is 164.9 million (31 Jul 25). Stockholders’ equity swung to $119.9 million from a $(0.5) million deficit.
- Restructuring: 40 % workforce cut; $3.0 million charges booked.
- Pipeline: CX-2051 showed 28 % ORR (43 % at 10 mg/kg) in Phase 1 colorectal cancer; dose expansions ongoing. CX-801 monotherapy escalation at dose-level 4; Keytruda combo started.
- Collaborations: Amgen EGFR TCE and BMS CTLA-4 licenses ended; remaining deferred revenue $32.3 million expected through 2027.
- Balance-sheet risk: $4.2 million uncertain tax liability from California audit.